Barlesi F, Mazieres J, Merlio J-P, Debieuvre D, Mosser J, Lena H et al (2016) Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT). Lancet 387:1415–1426

Article  CAS  PubMed  Google Scholar 

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A et al (2021) Global Cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71:209–249

Article  PubMed  Google Scholar 

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:394–424

Article  PubMed  Google Scholar 

Jordan EJ, Kim HR, Arcila ME, Barron D, Chakravarty D, Gao J et al (2017) Prospective comprehensive molecular characterization of lung adenocarcinomas for efficient patient matching to approved and emerging therapies. Cancer Discov 7:596–609

Article  CAS  PubMed  PubMed Central  Google Scholar 

Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A et al (2016) Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med 375:1823–1833

Article  CAS  PubMed  Google Scholar 

Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP et al (2015) Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 372:2018–2028

Article  PubMed  Google Scholar 

Herbst RS, Baas P, Kim D-W, Felip E, Pérez-Gracia JL, Han J-Y et al (2016) Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 387:1540–1550

Article  CAS  PubMed  Google Scholar 

Ayers KL, Mullaney T, Zhou X, Liu JJ, Lee K, Ma M et al (2021) Analysis of real-world data to investigate the impact of race and ethnicity on response to programmed cell death-1 and programmed cell death-ligand 1 inhibitors in advanced non-small cell lung cancers. Oncologist 26:e1226–e1239

Article  CAS  PubMed  PubMed Central  Google Scholar 

Patel K, Alpert N, Tuminello S, Taioli E (2022) Association of personal characteristics and effectiveness of immunotherapy in late-stage non-small cell lung cancer: a systematic review. JNCI Cancer Spectr 6:pkac015

Article  PubMed  PubMed Central  Google Scholar 

Butaney M, Satkunasivam R, Goldberg H, Freedland SJ, Patel SP, Hamid O et al (2020) Analysis of heterogeneity in survival benefit of Immunotherapy in oncology according to patient demographics and performance status: a systematic review and meta-analysis of overall survival data. Am J Clin Oncol 43:193–202

Article  PubMed  Google Scholar 

Ermer T, Canavan ME, Maduka RC, Li AX, Salazar MC, Kaminski MF et al (2022) Association between food and drug administration approval and disparities in immunotherapy use among patients with cancer in the US. JAMA Netw Open 5:e2219535

Article  PubMed  PubMed Central  Google Scholar 

Klugman M, Xue X, Hosgood HD (2019) Race/ethnicity and lung cancer survival in the United States: a meta-analysis. Cancer Causes Control 30:1231–1241

Article  PubMed  Google Scholar 

Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R et al (2018) Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. N Engl J Med 379:2342–2350

Article  CAS  PubMed  Google Scholar 

Albain KS, Unger JM, Crowley JJ, Coltman CA, Hershman DL (2009) Racial disparities in cancer survival among randomized clinical trials patients of the Southwest Oncology Group. J Natl Cancer Inst 101:984–992

Article  PubMed  PubMed Central  Google Scholar 

Aizer AA, Wilhite TJ, Chen M-H, Graham PL, Choueiri TK, Hoffman KE et al (2014) Lack of reduction in racial disparities in cancer-specific mortality over a 20-year period. Cancer 120:1532–1539

Article  PubMed  Google Scholar 

Katkade VB, Sanders KN, Zou KH (2018) Real world data: an opportunity to supplement existing evidence for the use of long-established medicines in health care decision making. J Multidiscip Healthc 11:295–304

Article  PubMed  PubMed Central  Google Scholar 

Florez MA, Kemnade JO, Chen N, Du W, Sabichi AL, Wang DY et al (2022) Persistent ethnicity-associated disparity in anti-tumor effectiveness of immune checkpoint inhibitors despite equal access. Cancer Res Commun 2022:806–813

Article  PubMed  Google Scholar 

Lee M, Liu J, Miao E, Wang S, Zhang F, Wei J et al (2023) Similar efficacy observed for first-line immunotherapy in racial/ethnic minority patients with metastatic NSCLC. J Natl Compr Canc Netw 21:1269-1280e5

Article  CAS  PubMed  Google Scholar 

Priantti JN, Vilbert M, de Moraes FCA, Madeira T, de Lima Santiago EM, Leighl NB et al (2024) Neurocognitive adverse events related to lorlatinib in non-small cell lung cancer: a systematic review and meta-analysis. Cancers 16:2611

Article  CAS  PubMed  PubMed Central  Google Scholar 

de Moraes FCA, Lôbo A, de OM, Sano VKT, Kelly FA, Burbano RMR (2024) Treatment-related adverse events, including fatal toxicities, in patients with extensive-stage small cell lung cancer receiving adjuvant PD-1/PD-L1 inhibitors: a meta-analysis and trial sequential analysis of randomized controlled trials. Clin Oncol 36(10):e408–e419. https://doi.org/10.1016/j.clon.2024.06.056

Article  Google Scholar 

American Joint Committee on Cancer | SEER Training [Internet] [cited 2024 Mar 3]. https://training.seer.cancer.gov/staging/systems/ajcc/

Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I et al (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 366:l4898

Article  PubMed  Google Scholar 

Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71

Article  PubMed  PubMed Central  Google Scholar 

Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629–634

Article  CAS  PubMed  PubMed Central  Google Scholar 

DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7:177–188

Article  CAS  PubMed  Google Scholar 

IntHout J, Ioannidis JPA, Borm GF (2014) The Hartung-Knapp-Sidik-Jonkman method for random effects meta-analysis is straightforward and considerably outperforms the standard DerSimonian-Laird method. BMC Med Res Methodol 14:25

Article  PubMed  PubMed Central  Google Scholar 

Lu S, Zhang W, Wu L, Wang W, Zhang P (2024) Neotorch investigators. perioperative toripalimab plus chemotherapy for patients with resectable non–small cell lung cancer: the neotorch randomized clinical trial. JAMA 331:201–211

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wakelee H, Liberman M, Kato T, Tsuboi M, Lee S-H, Gao S et al (2023) Perioperative pembrolizumab for early-stage non-small-cell lung cancer. N Engl J Med 389:491–503

Article  CAS  PubMed  PubMed Central  Google Scholar 

O’Brien M, Paz-Ares L, Marreaud S, Dafni U, Oselin K, Havel L et al (2022) Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial. Lancet Oncol 23:1274–1286

Article  PubMed  Google Scholar 

Provencio M, Nadal E, González-Larriba JL, Martínez-Martí A, Bernabé R, Bosch-Barrera J et al (2023) Perioperative nivolumab and chemotherapy in stage III non-small-cell lung cancer. N Engl J Med 389:504–513

Article  CAS  PubMed  Google Scholar 

Felip E, Altorki N, Zhou C, Csőszi T, Vynnychenko I, Goloborodko O et al (2021) Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial. Lancet 398:1344–1357

Article  CAS  PubMed